Accuray Incorporated (ARAY)


-0.05 (-2.16%)
Symbol ARAY
Price $2.26
Beta 1.916
Volume Avg. 0.70M
Market Cap 209.733M
Shares () -
52 Week Range 2.08-5.93
1y Target Est -
DCF Unlevered ARAY DCF ->
DCF Levered ARAY LDCF ->
ROE -23.92% Sell
ROA -2.77% Neutral
Operating Margin -
Debt / Equity 809.60% Strong Buy
P/E -
P/B 4.02 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest ARAY news

Mr. Joshua Levine
Medical Devices
NASDAQ Global Select

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney. The company also provides the TomoTherapy System, including the Radixact System, which consists of an integrated radiation therapy system designed for the treatment of a range of cancer types. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.